The Microbiome-based Therapeutics R&D sector is projected to maintain its double-digit growth throughout 2026, following a transformative “boom” year in 2025. With the human microbiome market size now exceeding $1.6 billion, the focus has shifted toward targeted microbial strains and AI-driven drug discovery. Using Linknovate’s proprietary data, including biotech patent analytics, Venture Capital (VC) trends, and clinical trial milestones, we’ve mapped the most influential companies in the...